tiprankstipranks
Advertisement
Advertisement

ONC Stock Latest News

BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
The FlyBeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial
17h ago
ONC
Early Data Milestone: BeOne Medicines Advances BGB-15025 in Immune Oncology
PremiumCompany Announcements
Early Data Milestone: BeOne Medicines Advances BGB-15025 in Immune Oncology
4d ago
ONC
BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope
PremiumCompany Announcements
BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope
5d ago
ONC
BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial
PremiumCompany Announcements
BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial
12d ago
ONC
BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors
PremiumCompany Announcements
BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors
12d ago
ONC
BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
PremiumCompany AnnouncementsBeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
13d ago
ONC
BeOne Medicines announces presentation of Phase 3 data in CLL patients
Premium
The Fly
BeOne Medicines announces presentation of Phase 3 data in CLL patients
20d ago
ONC
BeOne Medicines Advances CDK4 Cancer Drug With Completion of Key Phase 1 Trial
Premium
Company Announcements
BeOne Medicines Advances CDK4 Cancer Drug With Completion of Key Phase 1 Trial
20d ago
ONC
BeOne Medicines Completes First-in-Human Study of New B7H3 Cancer Drug
PremiumCompany Announcements
BeOne Medicines Completes First-in-Human Study of New B7H3 Cancer Drug
22d ago
ONC
AI Models Turn Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
PremiumAI Analyst Ratings
AI Models Turn Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
26d ago
ONC
BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race
PremiumCompany Announcements
BeOne Medicines Halts Early KRAS Trial, Resetting Expectations in a Crowded Oncology Race
27d ago
ONC
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
PremiumCompany Announcements
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
27d ago
ONC
ZYME
BeOne Medicines price target raised to $436 from $425 at RBC Capital
PremiumThe FlyBeOne Medicines price target raised to $436 from $425 at RBC Capital
28d ago
ONC
New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors
Premium
Company Announcements
New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors
1M ago
ONC
BeOne Medicines’ combination shows improved survival in adenocarcinoma
Premium
The Fly
BeOne Medicines’ combination shows improved survival in adenocarcinoma
1M ago
ONC
BeOne Medicines Advances First-in-Human Solid Tumor Trial With BG-C0979
PremiumCompany Announcements
BeOne Medicines Advances First-in-Human Solid Tumor Trial With BG-C0979
1M ago
ONC
BeOne Medicines Pits New Breast Cancer Drug Against CDK4/6 Leaders in Phase 3 Test
PremiumCompany Announcements
BeOne Medicines Pits New Breast Cancer Drug Against CDK4/6 Leaders in Phase 3 Test
1M ago
ONC
BeOne Medicines Halts Early Lung Cancer Trial, Resetting Expectations for EGFR Pipeline
PremiumCompany Announcements
BeOne Medicines Halts Early Lung Cancer Trial, Resetting Expectations for EGFR Pipeline
1M ago
ONC
BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
PremiumCompany Announcements
BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
2M ago
8K
ONC
BeOne Medicines price target raised to $367 from $364 at Leerink
PremiumThe FlyBeOne Medicines price target raised to $367 from $364 at Leerink
2M ago
ONC
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
Premium
The Fly
BeOne Medicines’ Beqalzi granted accelerated approval by FDA
2M ago
ONC
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Premium
The Fly
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
2M ago
ONC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >